The gold and silver miner released its third-quarter 2018 production report.
A recently announced debt financing won't dilute shareholders, but it still has Wall Street worried.
Economic fears are pushing gold prices higher. Struggling gold stocks are following suit.
It can't be said enough: The U.S. will be a net energy exporter by 2022. These two stocks will help you to cash in.
Enthusiasm for the biopharma is wearing off despite its announcement of an important commercial milestone.
A share offering didn't help. Investors also began to wonder: Was a $2.5 billion market cap justified?
The biopharma's multimonth stock slide continued, courtesy of promising preclinical results released by Amgen.
Investors received good news from the clinic for an important development-stage asset.
The genetic testing leader's year-to-date momentum continued for yet another month. Should investors be concerned by the streak's abrupt end in October?
The double-digit move follows a 67.5% leap in August, but was followed by a 19% drop in the first 10 days of October.
The stock recovered from a surprising rejection at the end of August, but has tumbled once again in the first half of October.
A Wall Street analyst turned bullish -- and the market responded in kind. But investors may want to consider the binary nature of this biopharma stock.
But the stock has fallen 20% in October as of this writing. Should investors be concerned?
The FDA issued a positive statement on the company's drug for Parkinson's disease psychosis, but investors still need to watch one important metric.
The paint and coatings specialist warned of weak upcoming third-quarter 2018 results.
Both stocks have gained over 140% in the last year alone. Both are looking forward to growth from innovative sweetener ingredients. One doesn't belong in your portfolio.
The renewable-energy leader expects to grow its dividend by at least 12% each year through 2023. Investors will find the argument for success pretty persuasive.
The company presented at a healthcare conference for the first time since announcing REDUCE-IT trial results in September.
The pharma company announced the pricing of a share offering.
It's official: A judge ruled that Fresenius can abandon the previously announced acquisition of Akorn.